



## Clinical trial results:

**Evaluation of efficacy and safety of Ibuprofen Arginine 600 mg tid vs. Ibuprofen 600 mg tid in the treatment of pain and inflammation in Osteoarthritis (OA) patients with hypertension pharmacologically stabilized.**

### Summary

EudraCT number	2011-003826-28
Trial protocol	IT
Global end of trial date	09 December 2013

### Results information

Result version number	v1 (current)
This version publication date	17 December 2016
First version publication date	17 December 2016
Summary attachment (see zip file)	CSR synopsis Z7190L01 (Sinossi 12 Jan 2015.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	Z7190L01
-----------------------	----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Zambon SpA
Sponsor organisation address	via Lillo Del Duca 10, Bresso, Italy,
Public contact	Sponsor Contact Point, Zambon S.p.A., +39 0266524513, clinicaltrials@zambongroup.com
Scientific contact	Sponsor Contact Point, Zambon S.p.A., +39 0266524513, clinicaltrials@zambongroup.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	23 May 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 December 2013
Global end of trial reached?	Yes
Global end of trial date	09 December 2013
Was the trial ended prematurely?	Yes

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The objective of the study is to compare IBA vs. IBU in the change from baseline of daily spontaneous pain in patients suffering from OA and stabilized hypertension.

Protection of trial subjects:

No specific measures were in place. The test and reference products are marketed products.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 March 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Italy: 10
Worldwide total number of subjects	10
EEA total number of subjects	10

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	6
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was performed in Italy at 4 investigational study sites (public hospitals). Patients were affected by osteoarthritis (OA) with hypertension.

### Pre-assignment

Screening details:

After signing the informed consent, patients with OA and stabilized hypertension by pharmacological treatment in monotherapy or with no more than three antihypertensive drugs association among AT1 antagonists or ACE inhibitors or Calcium-channel-blockers or diuretics .

### Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ibuprofen arginine

Arm description:

14 days treatment with Ibuprofen Arginine apricot 600 mg

Arm type	Experimental
Investigational medicinal product name	Ibuprofen arginine
Investigational medicinal product code	Z7190
Other name	
Pharmaceutical forms	Granules for oral solution
Routes of administration	Oral use

Dosage and administration details:

600 mg three times daily

<b>Arm title</b>	Ibuprofen
------------------	-----------

Arm description:

14 days treatment with ibuprofen 600 mg

Arm type	Active comparator
Investigational medicinal product name	Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Granules for oral solution
Routes of administration	Oral use

Dosage and administration details:

600 mg three times daily

<b>Number of subjects in period 1</b>	Ibuprofen arginine	Ibuprofen
Started	5	5
Completed	5	5

## Baseline characteristics

### Reporting groups

Reporting group title	Ibuprofen arginine
Reporting group description: 14 days treatment with Ibuprofen Arginine apricot 600 mg	
Reporting group title	Ibuprofen
Reporting group description: 14 days treatment with ibuprofen 600 mg	

Reporting group values	Ibuprofen arginine	Ibuprofen	Total
Number of subjects	5	5	10
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	70.6	68.3	
standard deviation	± 7.9	± 8.9	-
Gender categorical Units: Subjects			
Female	3	5	8
Male	2	0	2

### Subject analysis sets

Subject analysis set title	FAS IBA
Subject analysis set type	Full analysis
Subject analysis set description: only 5 randomized subjects who took one dose of IMP are reported. Study has been interrupted and therefore no formal analysis has been performed	
Subject analysis set title	FAS IBU
Subject analysis set type	Full analysis
Subject analysis set description: only 5 randomized subjects who took one dose of IMP are reported. Study has been interrupted and therefore no formal analysis has been performed	

Reporting group values	FAS IBA	FAS IBU	
Number of subjects	5	5	
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years arithmetic mean standard deviation	67.1 ± 8.7	±	
Gender categorical Units: Subjects			
Female	8		
Male	2		

## End points

### End points reporting groups

Reporting group title	Ibuprofen arginine
Reporting group description: 14 days treatment with Ibuprofen Arginine apricot 600 mg	
Reporting group title	Ibuprofen
Reporting group description: 14 days treatment with ibuprofen 600 mg	
Subject analysis set title	FAS IBA
Subject analysis set type	Full analysis
Subject analysis set description: only 5 randomized subjects who took one dose of IMP are reported. Study has been interrupted and therefore no formal analysis has been performed	
Subject analysis set title	FAS IBU
Subject analysis set type	Full analysis
Subject analysis set description: only 5 randomized subjects who took one dose of IMP are reported. Study has been interrupted and therefore no formal analysis has been performed	

### Primary: change versus baseline of daily spontaneous pain on VAS

End point title	change versus baseline of daily spontaneous pain on VAS <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: change from Day 0 to Day 14	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to study prematurely termination, no formal statistical analysis has been performed due to low number of subjects	

End point values	Ibuprofen arginine	Ibuprofen	FAS IBA	FAS IBU
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	5	5
Units: mm				
arithmetic mean (standard deviation)	58.8 (± 30.8)	57.6 (± 25.5)	41 (± 39.4)	45.2 (± 32.2)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Daily morning stiffness

End point title	Daily morning stiffness
End point description:	
End point type	Secondary

---

End point timeframe:  
from day 0 to day 14

---

End point values	Ibuprofen arginine	Ibuprofen	FAS IBA	FAS IBU
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	5	5
Units: mm				
arithmetic mean (standard deviation)	60.6 (± 25.2)	50.8 (± 25.3)	40.3 (± 39.1)	44.8 (± 32.2)

### Statistical analyses

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are reported from enrolment to end of study (e.g. day 14)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	safety population IBA
-----------------------	-----------------------

Reporting group description:

all subjects treated with at least one dose of IMP

Reporting group title	Safety Population IBU
-----------------------	-----------------------

Reporting group description: -

Serious adverse events	safety population IBA	Safety Population IBU	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	0 / 5 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	safety population IBA	Safety Population IBU	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 5 (20.00%)	1 / 5 (20.00%)	
General disorders and administration site conditions			
Oedema			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 November 2012	This amendment changed the method for the assessment of kidney disease as exclusion criterion, i.e. the Cockcroft-Gault formula was replaced with the MDRD formula, as it was considered as more reliable than the Cockcroft-Gault formula. With the MDRD formula, a value of estimated GFR below 60 ml/min is indicative of chronic renal disease.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
02 December 2013	It was initially expected that recruitment would be completed over a period of one year starting from the 2nd quarter of 2012. The actual recruitment was slower than expected and recruitment was eventually terminated in November 2013 with only 10 patients randomized.	-

Notes:

### Limitations and caveats

None reported